← Back to Browse

United Therapeutics Corporation

UTHR • Healthcare

Compare

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity.

Current Price
$547.06
Market Cap
$18.4B

Quality Assessment

United Therapeutics Corporation is a high-quality healthcare company with a Compass Score of 98. Profitability, cash flow, and price stability all score well here. The kind of stock long-term investors tend to hold for quality.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Wall Street View

Consensus
Buy
Analysts
10
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
๐Ÿ”’
EPS Beat Streak
๐Ÿ”’
Net Upgrades (180d)
๐Ÿ”’

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.